Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) marched up 190.49% compared to a 52-week low price of $6.31. The shares were last seen trading -3.83% lower, taking the closing price at $18.32 on 4/12/2019. At a recent session, the prices were hovering between $18.115 and $19.35. This company shares are 32.37% off its target price of $24.25 and the current market capitalization stands at $1.67B. The recent change has given its price a 1.46% lead over SMA 50 and -18.18% deficit over its 52-week high. The stock witnessed -1.24% declines, 23.2% gains and 44.94% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ARWR’s volatility during a week at 4.28% and during a month it has been found around 4.13%.Arrowhead Pharmaceuticals, Inc. (ARWR) Top Holders
Institutional investors currently hold around $1.07 billion or 63.8% in ARWR stock. Look at its top three institutional owners: Oppenheimerfunds, Inc. owns $143.01 million in Arrowhead Pharmaceuticals, Inc., which represents roughly 8.56% of the company’s market cap and approximately 13.33% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 7,184,621 shares of the stock are valued at $131.62 million. The third largest holder is Rtw Investments, Lp, which currently holds $97.39 million worth of this stock and that ownership represents nearly 5.83% of its market capitalization.
At the end of December reporting period, 100 institutional holders increased their position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by some 10,098,895 shares, 67 decreased positions by 7,396,746 and 16 held positions by 41,055,952. That puts total institutional holdings at 58,551,593 shares, according to SEC filings. The stock grabbed 57 new institutional investments totaling 6,064,576 shares while 24 institutional investors sold out their entire positions totaling 2,572,657 shares.Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Insider Trades
Multiple company employees have indulged in significant insider trading. Arrowhead Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that CEO Anzalone Christopher Richard has sold 50,000 shares of Arrowhead Pharmaceuticals, Inc. (ARWR) in the trading session dated Apr. 03, 2019. These shares are worth $965,000 and were traded at $19.3 each. The SEC filing shows that GIVEN BRUCE D performed a sale of 42,500 shares. The COO disposed these shares by way of transaction on Mar. 01, 2019. The company’s shares were given away at $19.99 per share worth to an income of some $849,575 to the account of GIVEN BRUCE D.
COO, GIVEN BRUCE D, sold 42,500 common shares of Arrowhead Pharmaceuticals, Inc. (ARWR) in the open market. In a transaction dated Feb. 25, 2019, the shares were put up for sale at an average price of $18.98, raking in a sum of $806,650. After this sale, 644,606 common shares of ARWR are directly owned by the insider, with total stake valued at $11,809,182.
In the transaction dated Feb. 19, 2019, a great number of shares sold came courtesy the CFO; Myszkowski Kenneth Allen disposed a total of 8,000 shares at an average price of $18, amounting to approximately $144,000. The insider now directly owns 305,607 shares worth $5,598,720.Arrowhead Pharmaceuticals, Inc. (ARWR) Analyst Guide
Several analysts have released their opinion on Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), with 2 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 4 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.67 average brokerage recommendation [T1].